Lipton RB, et al. - Researchers evaluated DFN-02 — a nasal spray comprising sumatriptan 10 mg and a permeation-enhancing excipient (0.2% 1-O-n-Dodecyl-β-D-Maltopyranoside [DDM]) - regarding efficacy, safety, and tolerability for the acute treatment of migraine with or without aura in adults. They undertook a multicenter, randomized, 2-period, double-blind, placebo-controlled efficacy, safety, and tolerability phase 2 study of DFN-02. The preliminary results demonstrated DFN-02 as effective, well tolerated, and safe in the acute treatment of episodic migraine.